DocMorris today reported third-quarter external revenue of CHF 342.7 million, up 21.5 per cent in local currency, and said it had already reached its targeted adjusted EBITDA breakeven, posting CHF 0.6 million for the three months to September. The Swiss-listed online pharmacy, whose German business accounts for almost all of its sales, raised its full-year guidance for the second time this year on the back of prescription revenue that grew 78.3 per cent year-on-year. Its advertising arm, folded into a segment called Digital Services, grew 46.1 per cent to CHF 13.9 million - exactly the figure it posted in the second quarter.

In Short

DocMorris, a big online pharmacy that mostly sells to people in Germany, sold far more prescription medicine this summer than a year ago and, on its adjusted measure, earned slightly more than it spent before interest, tax, depreciation and amortisation. If you buy ads on pharmacy websites or follow European retail media, this matters because DocMorris sells advertising to health brands and puts that business in a unit that grew 46.1 per cent year-on-year but did not grow at all from the previous quarter. The company now expects a better 2026 than it said in August, though it still does not publish how much of its revenue comes from ads.

The quarter in numbers

The release, issued as an ad hoc announcement under Article 53 of the SIX Swiss Exchange listing rules at 07:00 CET on October 15, 2026, from DocMorris' base in Frauenfeld, carries a table of key figures marked "unaudited". Every growth rate in the text is given in local currency, according to a footnote in the release. The table adds the reported Swiss franc changes alongside.

For the third quarter, DocMorris external revenue reached CHF 342.7 million, compared with CHF 282.3 million in the same period of 2025. That is an increase of 21.4 per cent in francs and 21.5 per cent in local currency. Revenue - a narrower measure - rose to CHF 327.4 million from CHF 268.1 million, an increase of 22.1 per cent reported and 22.2 per cent in local currency.

The difference between the two lines matters. According to DocMorris, external revenue "consists of the revenue of DocMorris plus online revenue of apotal, less revenue related to supplies to apotal." In the third quarter, that gap amounted to CHF 15.3 million. The release does not explain the commercial arrangement with apotal in further detail, and all headline growth rates in the release refer to external revenue rather than to the revenue line that appears in statutory accounts.

The segment Germany carried almost the entire quarter. Its external revenue rose to CHF 326.3 million from CHF 267.6 million, up 22.0 per cent in local currency. Germany revenue reached CHF 311.0 million, up 22.8 per cent. The segment Europe - which the company does not break down by country in the release - grew revenue 12.0 per cent in local currency to CHF 16.4 million from CHF 14.6 million.

Prescriptions now a third of German sales

Prescription medicines, labelled Rx in the release, drove the acceleration. Germany Rx external revenue reached CHF 108.1 million in the third quarter, against CHF 60.9 million a year earlier, a rise of 77.6 per cent in francs and 78.3 per cent in local currency. According to DocMorris, Rx external revenue was also 33.5 per cent higher than in the second quarter of 2026, which had itself been up 17.0 per cent on the first quarter.

Those two sequential figures describe a curve that is steepening, not flattening. Rx accounted for about 33 per cent of Germany external revenue in the third quarter, compared with about 23 per cent in the same quarter of 2025, by PPC Land's calculation from the table. The release does not give the number of prescriptions processed, average basket value, or the share of prescriptions arriving electronically, so it is not possible to separate volume growth from price or mix effects.

Non-Rx external revenue in Germany - which, according to a footnote, consists of the OTC business plus Digital Services - grew 5.5 per cent to CHF 218.2 million from CHF 206.8 million. The OTC business itself "grew as planned by 3.5 per cent," according to DocMorris. The release does not state what the plan was.

Customers

The number of active customers increased by 1.5 million year-on-year to 13.1 million, according to DocMorris. Only 0.2 million of those were added during the third quarter itself, "with the number of new Rx customers increasing at an above-average rate." The release defines active customers as "customers supplied by DocMorris, either directly or through its partners," but does not specify the look-back window used to count a customer as active, nor how many of the 13.1 million are Rx customers.

The difference between the annual and quarterly additions is notable. An increase of 1.5 million over twelve months, of which 0.2 million came in the most recent three, implies that 1.3 million were added between October 2025 and June 2026. Revenue growth accelerated in the third quarter while customer additions slowed - consistent with existing customers spending more, though the release does not say so directly.

Breakeven, ahead of schedule

DocMorris achieved adjusted EBITDA of CHF 0.6 million in the third quarter, "thus reaching the targeted breakeven ahead of schedule," according to the company. Chief financial officer Daniel Wüest attributed the result to "the strong performance of Rx and Digital Services, as well as further improvements in cost and marketing efficiency."

Several items that would normally accompany a profitability milestone are absent. The release does not give adjusted EBITDA for the first nine months, for the second quarter, or for the third quarter of 2025, so the size of the improvement cannot be measured from the document. It does not define which items are excluded to reach the "adjusted" figure. It gives no marketing expense figure, despite naming marketing efficiency as one of the drivers. And it does not report net income, operating cash flow or cash on hand. CHF 0.6 million on revenue of CHF 327.4 million is a margin of about 0.2 per cent - a threshold crossed, but narrowly.

The marketing reference is the closest the release comes to DocMorris' role as a buyer of media rather than a seller of it. The company says only that marketing became more efficient, without quantifying the change or naming channels.

Cost reduction was already on the table before the quarter began. On June 25, 2026, DocMorris set out an accelerated "AI-First" strategy targeting at least CHF 15 million in annual savings and the removal of around 100 full-time positions. Retail media was named as one of the platform pillars to be protected from those cuts. The October 15 release does not mention the programme or update its progress.

Raised guidance, and what it implies

DocMorris raised its 2026 guidance "due to continued positive current trading." The changes are:

  • External revenue growth of 12.5 to 15 per cent, up from 9 to 13 per cent previously.
  • Adjusted EBITDA better than minus CHF 10 million, compared with minus CHF 10 million to minus CHF 17.5 million previously.
  • Capital expenditure unchanged at below CHF 30 million.

The release describes the move as raising guidance "again," without listing the earlier ranges or the date of the previous revision.

The EBITDA guidance is the more revealing number. A full-year figure "better than minus CHF 10 million," combined with a positive third quarter, implies that the first half carried a substantial loss. The release does not give that loss, and no figure for the fourth quarter is offered either. The new floor is also open-ended: "better than" sets a ceiling on the loss but no expected point.

The revenue range invites a rough check. DocMorris' boilerplate gives 2025 external revenue as CHF 1,186 million. Growth of 12.5 to 15 per cent on that base points to roughly CHF 1,334 million to CHF 1,364 million for 2026. With CHF 970.6 million already booked in the first nine months, the remainder for the fourth quarter would be roughly CHF 364 million to CHF 393 million, against about CHF 331.7 million in the fourth quarter of 2025 (2025's full year less its nine-month figure). Those are PPC Land calculations that mix reported franc amounts with local-currency growth rates, so they are approximate. Even so, the bottom of the range would correspond to fourth-quarter growth well below the 21.5 per cent just reported - and the company also says Rx showed "a continued positive trend in the fourth quarter." Either the low end is conservative, or the company expects a slowdown it has not described.

Management confirmed its target of free cash flow breakeven "during 2027" and said medium-term targets remain unchanged. Those medium-term targets are not restated in the release.

Refinancing

In September 2026, DocMorris repurchased its CHF 49.6 million convertible bond maturing in 2028, financing the buyback with a new convertible bond maturing in 2031, according to the release. DocMorris says this extends its maturity profile while "reducing its relative financing costs." The size of the new bond, its coupon and its conversion price are not given.

Nine months

For January to September, external revenue rose to CHF 970.6 million from CHF 854.3 million, up 15.5 per cent in local currency but only 13.6 per cent in francs. Revenue reached CHF 926.6 million, up 16.4 per cent in local currency and 14.5 per cent reported. The roughly two-point gap between the two growth measures over nine months - compared with almost none in the third quarter alone - indicates that currency movements weighed on the franc figures earlier in the year.

Germany external revenue for the nine months was CHF 920.3 million, up 16.0 per cent in local currency. Germany Rx external revenue was CHF 256.0 million, up 52.6 per cent, from CHF 170.5 million. Germany non-Rx external revenue rose 6.2 per cent in local currency to CHF 664.2 million, and Europe revenue grew 6.3 per cent to CHF 50.3 million.

The advertising business inside Digital Services

For the advertising industry, the relevant line is Digital Services. According to DocMorris, the segment comprises TeleClinic, Retail Media and Marketplace. In the third quarter it "achieved revenue growth of 46.1 per cent to CHF 13.9 million, with a further increase in earnings contribution." Over nine months it grew 62.0 per cent to CHF 41.0 million.

DocMorris operates its retail media network as dmr Advertising. It launched in September 2023 with Criteo, offering Sponsored Product Ads and Native Brand Ads across the DocMorris and medpex webshops in Germany, added Native Video Ads in July 2024 after a nine-month internal test, and in October 2024 added a LiveRamp partnership covering measurement on closed social platforms and the LiveRamp Clean Room, powered by Habu - the kind of clean room setup that lets advertisers match their own data against a retailer's without exchanging raw records.

Three things stand out in today's figures.

First, Digital Services revenue did not grow from the second quarter to the third. In July, the segment posted CHF 13.9 million in the second quarter, up 80.0 per cent, and CHF 27.1 million in the first half. Today's nine-month figure of CHF 41.0 million less that first-half total leaves CHF 13.9 million for the third quarter - the same amount. The year-on-year rate fell from 80.0 per cent to 46.1 per cent, partly because the comparison base grew: by PPC Land's calculation, the implied third-quarter 2025 figure is about CHF 9.5 million, against roughly CHF 7.7 million for the second quarter of 2025. The release does not comment on the sequential flatness, and summer seasonality in either telemedicine or advertising could account for some of it.

Second, the advertising component remains undisclosed. As in July, DocMorris reports retail media only as part of a bundle that includes a telemedicine platform - TeleClinic, which the company describes as Germany's largest, connecting patients with more than 6,500 doctors - and marketplaces for health and personal care products in Southern Europe. It is not possible to tell from the release whether advertising revenue rose, fell or held steady in the quarter. Nor is it clear whether all of Digital Services sits in the Germany segment, as the release's bullet structure suggests, given that the marketplaces it describes operate in Southern Europe. PPC Land's May coverage of Iberia's marketplace landscape listed PromoFarma by DocMorris as the dominant player in parapharmacy there.

Third, DocMorris says Digital Services increased its "earnings contribution," but gives no figure for it. The company names Digital Services as one of two drivers of the quarter's EBITDA. Still, at CHF 13.9 million, the segment is about 4 per cent of quarterly revenue.

Why the Rx surge matters for advertisers

The growth in prescription customers is the part of the release most relevant to the health brands that buy retail media on pharmacy sites. More Rx customers means more logged-in sessions from people who already have a confirmed relationship with the pharmacy - the kind of audience retail media networks sell against. The release does not say whether prescription customers are reachable through dmr Advertising, and promotion of prescription medicines to the public is heavily restricted in the EU, so the commercial link between the Rx line and the advertising line is indirect at best: it runs through OTC and personal care products that the same customers might buy.

The data side carries legal weight too. In a December 2025 ruling, the Administrative Court of Wiesbaden found that online pharmacy shopping carts can plausibly reveal health information, relying on the CJEU's October 2024 Lindenapotheke judgment that purchased pharmaceutical products can constitute health data even without a linked diagnosis. Data in that category - special category data under the GDPR - can be processed only on narrow grounds. Any pharmacy retail media operation that targets or measures audiences on purchase history works inside those limits. The October 15 release does not address data use at all.

The wider market

Retail media's financial picture this year has been mixed. Criteo, the technology partner behind dmr Advertising's launch, cut its full-year guidance on August 5, 2026 after second-quarter retail media revenue fell 21 per cent to $47.9 million, even as retail media media spend rose 31 per cent at constant currency to $527 million. Criteo attributed much of the decline to two clients whose engagement scope shrank. Omdia projected in September 2025 that retail media networks would exceed $300 billion in spending by 2030, about 20 per cent of global advertising revenue.

Online pharmacies also face constraints that general retailers do not. When Google added Shopping ads and free listings in 14 European markets in July, it barred over-the-counter and prescription drug listings in all 14. Certification demand for health advertisers continues to rise: LegitScript reported in September that telemedicine certification applications rose 101 per cent in a year, with Google requiring certification for telemedicine and online pharmacy ads in 11 markets. For a company like DocMorris, both pressures cut the same way: paid acquisition on third-party platforms comes with limits, which makes owned customer relationships - and the advertising inventory that comes with them - more valuable.

What the release leaves out

Summarising the gaps in one place:

  • No standalone retail media revenue, advertiser count, or media spend figure.
  • No adjusted EBITDA for the nine months, the second quarter, or the prior-year quarter, and no definition of the adjustments.
  • No marketing expense figure, despite "marketing efficiency" being cited as a driver.
  • No prescription volumes or electronic prescription share behind the 78.3 per cent Rx growth.
  • No look-back window for "active customers."
  • No terms for the new 2031 convertible bond.
  • No restatement of the medium-term targets described as unchanged.

All figures in the release are unaudited.

What comes next

DocMorris lists its Capital Markets Day in Heerlen, the Netherlands - where its main, highly automated logistics centre is located - for November 12, 2026. That event, already scheduled in July, is the most likely occasion for updated medium-term targets and, possibly, more detail on the Digital Services components. Revenue for 2026 follows on January 19, 2027, full-year results and the 2027 outlook on March 18, 2027, a first-quarter trading update on April 15, 2027, and the annual general meeting in Zurich on May 12, 2027.

Chief executive Walter Hess framed the quarter around patients rather than profit. "Our revenue growth accelerated again in the third quarter of 2026, demonstrating that our offering is well received by patients," he said. "We will continue to consistently leverage this Rx momentum to expand our customer base and further solidify our position in the digital healthcare market."

The company employs around 1,600 people in Germany, the Netherlands, Spain, France, Portugal and Switzerland, according to its boilerplate, and its shares trade on the SIX Swiss Exchange under the ticker DOCM.

Timeline

Summary

Who: DocMorris AG, the Swiss-listed online pharmacy group based in Frauenfeld, with chief executive Walter Hess and chief financial officer Daniel Wüest. Its German business, its TeleClinic telemedicine platform, its dmr Advertising retail media unit and its Southern European marketplaces all sit inside the figures.

What: Third-quarter external revenue rose 21.5 per cent in local currency to CHF 342.7 million, German prescription revenue grew 78.3 per cent, adjusted EBITDA reached CHF 0.6 million, and 2026 guidance was raised to external revenue growth of 12.5 to 15 per cent and adjusted EBITDA better than minus CHF 10 million. Digital Services, which contains retail media, grew 46.1 per cent year-on-year to CHF 13.9 million but was flat against the second quarter, and no separate advertising figure was disclosed.

When: The ad hoc announcement was issued today, October 15, 2026, at 07:00 CET, covering the quarter to September 30. A Capital Markets Day follows on November 12, 2026.

Where: Almost all revenue comes from Germany, with smaller operations elsewhere in Europe; deliveries leave mainly from Heerlen, the Netherlands, and the shares trade on the SIX Swiss Exchange.

Why: For marketers, DocMorris is one of the larger pharmacy retail media networks in Europe, and its growing base of prescription customers is the audience that network sells around. The release shows the parent company crossing into adjusted profitability and its advertising segment growing year-on-year, while still withholding the numbers that would let health brands judge the scale of the advertising business itself.